Theranostic in GLP-1R molecular imaging: challenges and emerging opportunities.

Abstract

Theranostic in nuclear medicine combines diagnostic imaging and internal irradiation therapy using different therapeutic nuclear probes for visual diagnosis and precise treatment. GLP-1R is a popular receptor target in endocrine diseases, non-alcoholic steatohepatitis, tumors, and other areas. Likewise, it has also made breakthroughs in the development of molecular imaging. It was recognized that GLP-1R imaging originated from the study of insulinoma and afterwards was expanded in application including islet transplantation, pancreatic β-cell mass measurement, and ATP-dependent potassium channel-related endocrine diseases. Fortunately, GLP-1R molecular imaging has been involved in ischemic cardiomyocytes and neurodegenerative diseases. These signs illustrate the power of GLP-1R molecular imaging in the development of medicine. However, it is still limited to imaging diagnosis research in the current molecular imaging environment. The lack of molecular-targeted therapeutics related report hinders its radiology theranostic. In this article, the current research status, challenges, and emerging opportunities for GLP-1R molecular imaging are discussed in order to open a new path for theranostics and to promote the evolution of molecular medicine.

• Authors: Yang Xie, Yudi Wang, Wenjie Pei, Yue Chen
• Journal: Frontiers in molecular biosciences (Front Mol Biosci) Vol. 10 Pg. 1210347 ( 2023) ISSN: 2296-889X [Print] Switzerland
• PMID: 37780209 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2023 Xie, Wang, Pei and Chen.